Detecting and treating primary aldosteronism: Primary aldosteronism

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 3, 2007, Pages 171-174

  Mantero, F ^a   Matterello, M J ^a   Albiger, N M E ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Diagnosis; Primary aldosteronism; Treatment

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANRENOATE POTASSIUM; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FLUDROCORTISONE; POTASSIUM; PROGESTERONE RECEPTOR; SODIUM CHANNEL BLOCKING AGENT; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ADRENAL INCIDENTALOMA; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BODY POSTURE; CONGESTIVE HEART FAILURE; DIAGNOSTIC IMAGING; DRUG EFFECT; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; FAMILIAL DISEASE; FAMILY HISTORY; GYNECOMASTIA; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; IDIOPATHIC DISEASE; LAPAROSCOPIC SURGERY; LOADING TEST; MENSTRUAL IRREGULARITY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN RELEASE; REVIEW; SCREENING TEST; SODIUM INTAKE; STROKE; UNSPECIFIED SIDE EFFECT;

DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; ROC CURVE;

EID: 34247398619     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-970409     Document Type: Review

References (37)

1. Agharazii M, Douville P, Grose JH, Lebet M: Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37: 1440-1443
2. Armantini D, Karbowiak I, Goi A, Maniero F, Funder JW: In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential ant-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf) 1985; 23: 341-347
3. Carpenè G, Rocco G, Opocher G, Mantero F: Acute and chronic effect of nifedipine in primary aldosteronism. Clin Exper Hyper-Theory and practice 1989; 11: 1263-1272
4. Conn JW, Cohen EL, Rovner DR, Nesbit RM: Normokalemic primary aldosteronism, a detectable cause of curable "essential" hypertension. JAMA 1965; 193: 200-206
5. Conn JW: Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome, 1954. J Lab Clin Med 1990; 116: 253-267
6. Dupont A: Disappearence of spironolactone-induced gynecomastia during treatment with potassium canrenoate. Lancet 1985; 2: 731-734
7. Epstein M, Menard J, Alexander JC, Roniker B: Eplerenone, a novel and selective aldosterone receptor antagonist: efficacy in patients with mild to moderate hypertension. Circulation 2000; 98: S198-S199
8. Ghose RP, Hall PM, Bravo EL: Medical management of aldosterone-producing adenomas. Ann Intern Med 1999; 131: 105-108
9. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F: Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24 (4):737-745
10. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol 1994; 21: 315-318
11. Griffin GT, Melby JC: The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate in idiopathic hyperaldosteronism. J Clin Hypertens 1985; 1: 265-276
12. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T: A screening test to identify aldosterone producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141: 1589-1593
13. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez Sanchez CE: Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6: 717-723
14. Ignatowska-Switalska H, Chodakowska J, Januszewicz W, Feltynowski T, Adamczyk M, Lewondowski J: Evaluation of plasma aldosterone to plasma renin activity ratio in patients with primary aldosteronism. J Hum Hypertens 1997; 11: 373-378
15. Jackson RV, Lafferty A, Torpy DJ, Stratakis C: New genetic insights in familial hyperaldosteronism. Ann N Y Acad Sci 2002; 970: 77-88
16. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG: Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab 1997; 82: 3570-3573
17. McMahon GT, Dluhy RG: Glucocorticoid-remediable aldosteronism. Arq Bras Endocrinol Metabol 2004; 48: 682-686
18. Mantero F, Fallo F, Opocher G, Armanin D, Boscaro M, Scaroni C: Effect of angiotensin II and converting-enzyme inhibitor (captopril) on blood pressure, PRA and aldosterone in primary aldosteronism. Clin Sci (Lond) 1981; 61: S289-S293
19. Mantero F, Opocher G, Rocco S, Carpenè G, Armanini D: Long-term treatment of mineralocorticoid excess syndromes. Steroids 1995; 60: 81-86
20. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A: A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. Clin Endocrinol Metab 2000; 85: 637-644
21. Mulatero P, Rabbia F, Milan A, Paglieri C, Morellow F, Chiandussi L, Veglio F: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897-902
22. Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T: Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002; 51: 350-355
23. Pagny JY, Chatellier G, Raynaud A, Plouin PF, Corvol P: Localization of primary hyperaldosteronism. Ann Endocrinol (Paris) 1988; 49: 340-343
24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717
25. Pitt B, Remme W, Faiez Z, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321
26. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 2002; 283: H1802-H1810
27. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458
28. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F: High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertension 2002; 15: 896-902
29. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mollaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Sempiterni A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, PAPY Study Investigator; A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48 (11):2293-2300 Epub 2006 Nov 13
30. Sawka AN, Young WF, Thmpson GB, Grant CS, Farley DR, Leibson C, van Heerden J: Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001; 135: 258-261
31. Seifarth C, Trenkel S, Schobel H, Hahn EG, Hensen J: Influence of antihypertensive medication on aldosterone and rennin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol (Oxf) 2002; 57 (4):457-465
32. Seiler L, Rump LC, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, Beuschlein F, Reineke M: Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004; 150: 329-337
33. Stokes GS, Monaghan JC, Ryan M, Woodward M: Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism. J Hypertens 2001; 19: 1161-1165
34. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT: Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-1781
35. Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J: Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary aldosteronism. Exp Clin Endocrinol Diabetes 2002; 110 (2):80-85
36. Young WF, Stanson AW, Grant CSm Thompson GB, van Heerden JA: Primary aldosteronism: adrenal venous sampling. Surgery 1996; 120: 913-920
37. Young WF Jr: Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208-2213